CO2024004552A2 - Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3 - Google Patents
Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3Info
- Publication number
- CO2024004552A2 CO2024004552A2 CONC2024/0004552A CO2024004552A CO2024004552A2 CO 2024004552 A2 CO2024004552 A2 CO 2024004552A2 CO 2024004552 A CO2024004552 A CO 2024004552A CO 2024004552 A2 CO2024004552 A2 CO 2024004552A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds useful
- bicyclic heteroaryl
- fused bicyclic
- heteroaryl compounds
- nlrp3 inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21203314 | 2021-10-19 | ||
| EP22174872 | 2022-05-23 | ||
| PCT/EP2022/078755 WO2023066825A1 (en) | 2021-10-19 | 2022-10-17 | Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024004552A2 true CO2024004552A2 (es) | 2024-04-29 |
Family
ID=84359071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0004552A CO2024004552A2 (es) | 2021-10-19 | 2024-04-11 | Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240279237A1 (https=) |
| EP (1) | EP4419532A1 (https=) |
| JP (1) | JP2024539068A (https=) |
| KR (1) | KR20240088922A (https=) |
| AR (1) | AR127386A1 (https=) |
| AU (1) | AU2022369332A1 (https=) |
| CA (1) | CA3228369A1 (https=) |
| CL (1) | CL2024001106A1 (https=) |
| CO (1) | CO2024004552A2 (https=) |
| CR (1) | CR20240158A (https=) |
| IL (1) | IL310442A (https=) |
| MX (1) | MX2024004503A (https=) |
| PE (1) | PE20241176A1 (https=) |
| TW (1) | TW202330545A (https=) |
| WO (1) | WO2023066825A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CA3261365A1 (en) * | 2022-07-28 | 2024-02-01 | Ac Immune Sa | NEW COMPOUNDS |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| EP4667468A1 (en) * | 2023-02-14 | 2025-12-24 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound for inhibiting nlrp3, preparation method, and use |
| AU2024258000A1 (en) | 2023-04-19 | 2025-08-14 | F. Hoffmann-La Roche Ag | Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases |
| WO2025067343A1 (zh) * | 2023-09-27 | 2025-04-03 | 纽欧申医药(上海)有限公司 | 并环化合物及其应用 |
| WO2025099241A1 (en) * | 2023-11-10 | 2025-05-15 | Evotec International Gmbh | Nlrp3 modulators |
| US20250195511A1 (en) * | 2023-12-14 | 2025-06-19 | Merck Sharp & Dohme Llc | Indazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| TW202532066A (zh) * | 2023-12-14 | 2025-08-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之氮雜吲唑衍生物 |
| WO2025146160A1 (zh) * | 2024-01-05 | 2025-07-10 | 北京普祺医药科技股份有限公司 | 杂环化合物及其药物组合物 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025172260A1 (en) * | 2024-02-12 | 2025-08-21 | Evotec International Gmbh | Nlrp3 modulators |
| WO2025172521A1 (en) * | 2024-02-15 | 2025-08-21 | Evotec International Gmbh | Nlrp3 modulators |
| WO2026054623A1 (ko) * | 2024-09-09 | 2026-03-12 | (주) 업테라 | 신규 nlrp3 억제제 화합물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102116166B1 (ko) * | 2017-09-20 | 2020-05-27 | 건국대학교 글로컬산학협력단 | Nlrp3 억제제 |
| EP3953360B1 (en) | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
-
2022
- 2022-10-17 CA CA3228369A patent/CA3228369A1/en active Pending
- 2022-10-17 KR KR1020247012834A patent/KR20240088922A/ko active Pending
- 2022-10-17 EP EP22803219.9A patent/EP4419532A1/en active Pending
- 2022-10-17 MX MX2024004503A patent/MX2024004503A/es unknown
- 2022-10-17 AU AU2022369332A patent/AU2022369332A1/en active Pending
- 2022-10-17 JP JP2024523187A patent/JP2024539068A/ja active Pending
- 2022-10-17 WO PCT/EP2022/078755 patent/WO2023066825A1/en not_active Ceased
- 2022-10-17 AR ARP220102819A patent/AR127386A1/es unknown
- 2022-10-17 IL IL310442A patent/IL310442A/en unknown
- 2022-10-17 PE PE2024000806A patent/PE20241176A1/es unknown
- 2022-10-17 CR CR20240158A patent/CR20240158A/es unknown
- 2022-10-18 TW TW111139412A patent/TW202330545A/zh unknown
-
2024
- 2024-04-11 CL CL2024001106A patent/CL2024001106A1/es unknown
- 2024-04-11 CO CONC2024/0004552A patent/CO2024004552A2/es unknown
- 2024-04-17 US US18/637,966 patent/US20240279237A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240158A (es) | 2024-05-22 |
| KR20240088922A (ko) | 2024-06-20 |
| WO2023066825A1 (en) | 2023-04-27 |
| CA3228369A1 (en) | 2023-04-27 |
| JP2024539068A (ja) | 2024-10-28 |
| AU2022369332A1 (en) | 2024-02-08 |
| EP4419532A1 (en) | 2024-08-28 |
| AR127386A1 (es) | 2024-01-17 |
| MX2024004503A (es) | 2024-05-06 |
| IL310442A (en) | 2024-03-01 |
| US20240279237A1 (en) | 2024-08-22 |
| TW202330545A (zh) | 2023-08-01 |
| PE20241176A1 (es) | 2024-05-28 |
| CL2024001106A1 (es) | 2024-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024004552A2 (es) | Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3 | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| CL2020002423A1 (es) | Nuevos compuestos heterocíclicos | |
| CL2023003312A1 (es) | Inhibidores de nlrp3 | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| GT200700036A (es) | Compuestos fenil amido heterociclicos condensados | |
| MX2022002831A (es) | Compuestos heterociclicos. | |
| CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
| CL2023002429A1 (es) | Derivados novedosos de pirimidin-2-il sulfonamida | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| CL2023002362A1 (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| CO2020007222A2 (es) | Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida | |
| MX2022003023A (es) | Compuestos heterociclicos. | |
| CL2025001372A1 (es) | Derivados de triazinona como inhibidores de nlrp3. | |
| CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
| ECSP21011232A (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| MX2021011376A (es) | Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos. | |
| CO2022000186A2 (es) | Nuevos compuestos heterocíclicos | |
| UY38943A (es) | Nuevas heteroaril piperidiniletanonas sustituidas de 6 miembros | |
| CL2021000486A1 (es) | Derivados de heteroarilo bicíclicos | |
| CL2025000379A1 (es) | Compuestos derivados de tetrahidrotiazepina bicíclicos, composición farmacéutica, y uso como agentes inmunoterápicos. | |
| CO2025019059A2 (es) | Derivados de triazina como inhibidores de nlrp3 | |
| CO2025003011A2 (es) | Derivados bicíclicos de tetrahidrotiazepina |